Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities (2024 - 2026)

Recursion Pharmaceuticals' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• Quarterly Other Non-Current Liabilities fell 57.72% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 57.72% YoY) and the FY2025 annual result came in at $2.1 million, down 56.04% from the prior year.
• Other Non-Current Liabilities was $2.0 million for Q1 2026 at Recursion Pharmaceuticals, down from $2.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.8 million in Q1 2025 and bottomed at $1.0 million in Q3 2025.
• A 3-year average of $2.8 million and a median of $2.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 47.83% in 2025, while the deepest fall reached 65.69% in 2025.
• Recursion Pharmaceuticals' Other Non-Current Liabilities stood at $4.7 million in 2024, then slumped by 56.04% to $2.1 million in 2025, then decreased by 2.64% to $2.0 million in 2026.
• Business Quant data shows RXRX's Other Non-Current Liabilities at $2.0 million in Q1 2026, $2.1 million in Q4 2025, and $1.0 million in Q3 2025.